Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company pioneering transformative therapies for neurodegenerative diseases, recently hosted its Year-End Investor Webcast, providing stakeholders with a comprehensive overview of the company’s 2024 milestones and strategic initiatives for 2025. The full webcast is available here: https://youtu.be/NA3kCUZZIpI.
During the webcast, Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio, detailed significant progress in the company’s pivotal Phase 3 studies for Buntanetap, its lead drug candidate targeting neurodegenerative conditions such as Alzheimer’s and Parkinson’s diseases. These studies aim to demonstrate both symptomatic relief and disease-modifying effects, aligning with Annovis Bio’s mission to address the substantial unmet needs of patients and caregivers.
“2024 has been a year of significant progress for Annovis Bio, and we are excited about the opportunities ahead,” stated Dr. Maccecchini. “Our Phase 3 programs are designed to advance our understanding of neurodegeneration and bring us closer to delivering meaningful treatments that improve patients’ lives.”
The webcast also highlighted financial developments, including the recent securing of a $50 million At-The-Market (“ATM”) offering and ongoing strategic efforts to raise additional funds to support clinical trial development and long-term growth.
Webcast Highlights Include:
- Progress on pivotal Phase 3 Alzheimer’s and Parkinson’s clinical programs.
- Financial updates and future fundraising plans to support key initiatives.
- Insights into the company’s innovative approach targeting multiple neurotoxic proteins.
- Strategic plans for 2025 to drive regulatory and clinical milestones.
The event underscores Annovis Bio’s commitment to transparency and open communication with its investors as it continues to advance its mission to combat neurodegenerative diseases through innovative therapies.
About Annovis Bio Inc.
Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s (“AD”) and Parkinson’s (“PD”). The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients.
For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed), and Life Sciences sectors. It provides access to a network of wire solutions via InvestorWire to reach all target markets, industries, and demographics in the most effective manner possible. For more information, visit www.BioMedWire.com.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications
BioMedWire
Los Angeles, California
www.BioMedWire.com
310.299.1717 Office
[email protected]
About MissionIR
MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
For more information, please visit www.MissionIR.com
Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer
MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]
MissionIR is powered by IBN
